The October issue is out now! It features #BreastCancer Survivorship Program Navigates Long-Term Care, Global #LiverCancer Crisis Looms Without Action, Lancet Commission Warns, Not All Smoldering #Myeloma Needs Treatment, and more. Read it here: https://t.co/6OOWaWohxY

The #FDA approved darolutamide for metastatic castration-sensitive #ProstateCancer (mCSPC). The FDA previously approved darolutamide in combination with docetaxel for mCSPC. Read more: https://t.co/8uquvhkXL6

Every hour your mining equipment is down for repairs, you're bleeding money. The fleet management problem is actually a cash flow problem. @MiningDisrupt Nov 11-13. Let's discuss real solutions.

At 36, Heather Von St. James was diagnosed with malignant pleural #mesothelioma and given just 15 months to live. Nineteen years later, she’s not only surviving, but she’s also leading a movement. Listen to the podcast: https://t.co/aaT2g5GUlq @HeatherVSJ

A tough conversation in medicine involves an agonizing decision: Stop treatment and transition to hospice or try an unproven therapy in an early-phase trial or compassionate-use program? Read Dr. Harpham's full column here: https://t.co/Joq4w2uMOC

A recent analysis of patients with “good risk” ductal carcinoma in situ showed that tamoxifen decreased the risk of ipsilateral breast recurrence among individuals who opted for breast-conserving surgery without radiation. https://t.co/yx6kcO3asJ #DCIS

Looking for a delivery catheter to up-level your stroke intervention? Check out the recent clinical data to validate its real-world experience, delivering the aspiration catheter to the face of the clot in 100% of cases! Check out the article here.

Studies are examining treatment de-escalation strategies for patients with ductal carcinoma in situ. Read the collaboration with #UpToDate® here: https://t.co/JyWZm9hDDg #BreastCancer

A recent study revealed that approximately 8.9% of pediatric gliomas harbor alterations in fibroblast growth factor receptor family genes. https://t.co/GRvW4eEwTP

For a third consecutive term, St. Jude Children's Research Hospital has received the prestigious Magnet designation from the American Nurses Credentialing Center and, for the first time, achieved the Magnet with Distinction honor. https://t.co/uiM8fbIo67 @StJudeResearch

For survivors of #cancer who underwent diagnosis and treatment as adolescents and young adults, what are the long-term financial implications? Danielle Friedman, MD, MS, answers Three Questions. Read the column here: https://t.co/bqUaub7Qhy

FTMO Verified prop traders walk their path. Rise now and start your FTMO Challenge!

A #LancetCommission of international experts has issued an urgent call to reduce the global burden of #HepatocellularCarcinoma, warning that #LiverCancer incidence could nearly double by 2050. https://t.co/qQs9JENq8U

An updated #ASCO guideline offers practical recommendations for assessing, discussing, and offering #FertilityPreservation options not just at diagnosis, but throughout the cancer care continuum. Read more: https://t.co/BpF7SOXc56

Stay informed with curated content on #BRCA mutations, genetic testing, and disparities in care. The Hereditary Breast Cancer Resource Center is built for healthcare professionals like you. Visit it today! https://t.co/FevbHWnKjS #BreastCancerAwarenessMonth

The #FDA granted #AcceleratedApproval to dordaviprone, a protease activator, for adult and #pediatricpatients 1 year of age and older with diffuse midline #glioma harboring an H3 K27M mutation. Read more: https://t.co/EeD9Ob8tS0

During the Community Oncology Alliance's 2025 Community Oncology Conference, the role of #cannabis in #cancer care was discussed and debated. https://t.co/0LOyKgAv3H

"My journey to oncology began long before ever donning a white coat," writes Deepak Vadehra, DO. "I had known I wanted to be a doctor at a young age, but it was not until cancer hit home that I refocused on my goals for medicine." Read more: https://t.co/Iq9QtYFlLQ

Erik Sulman, MD, PhD, was recently appointed as the new Chair of the Department of Radiation Oncology at Duke University School of Medicine. https://t.co/HtjJyUpFMC

Both continuous and fixed-duration therapies are good options for #ChronicLymphocyticLeukemia patients, according to a presentation at the recent Great Debates & Updates in Hematologic Malignancies. https://t.co/ectyE3USC6 #CLL

“For patients with advanced cancers, detecting key biomarkers is essential to providing the best options for therapy,” says Jean-Paul De La O of Exact Sciences. Learn more about the OncoExTra® test and its ability to identify actionable bioarkers: https://t.co/dmPcSGLaGW

While receiving full approval from the European Medicines Agency, melphalan flufenamide, referred to as #Melflufen, was formally withdrawn by the U.S. #FDA. https://t.co/irkDE8YTwX

Annabelle Anandappa, MD, has received a Damon Runyon Physician-Scientist Training Award to support preclinical research on the use of RAS inhibitors to treat #AML. https://t.co/RpgnWcA0cf

“Our study has shown that steroids, especially at high doses given before and/or at the same time as immune checkpoint inhibitors, are the biggest independent predictor of ineffective immunotherapy in #NSCLC,” said Fumito Ito, MD, PhD. https://t.co/93B5cOgHrq